Experimental lung inflammation treatment trial shuts down after just one patient

NCT ID NCT04438382

Terminated Disease control Sponsor: ECOG-ACRIN Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The approach remains unproven.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab and intravenous immunoglobulin (IVIG)
What this could lead to: If it had succeeded, this could have pointed toward a better treatment for severe lung inflammation caused by immunotherapy in cancer patients.
What could go wrong: The trial was terminated early with only one participant, so no reliable conclusions can be drawn. The approach may not work or may have risks like infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm pneumonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MALIGNANT SOLID NEOPLASM STEROID-REFRACTORY PNEUMONITIS

Contacts and locations

Locations

Bronson Battle Creek

Battle Creek, Michigan, 49017, United States
Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Lakeland Hospital Niles

Niles, Michigan, 49120, United States
Lakeland Medical Center Saint Joseph

Saint Joseph, Michigan, 49085, United States
Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Mercy Health Mercy Campus

Muskegon, Michigan, 49444, United States
Mercy Health Saint Mary's

Grand Rapids, Michigan, 49503, United States
Metro Health Hospital

Wyoming, Michigan, 49519, United States
Munson Medical Center

Traverse City, Michigan, 49684, United States
Northwestern University

Chicago, Illinois, 60611, United States
Spectrum Health Reed City Hospital

Reed City, Michigan, 49677, United States
Spectrum Health at Butterworth Campus

Grand Rapids, Michigan, 49503, United States
VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235, United States
Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298, United States
West Michigan Cancer Center

Kalamazoo, Michigan, 49007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.